Costly cancer drugs trigger proposals to modify clinical trial design.
Schmidt
Charlie
C
D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D000068258:Bevacizumab; D002986:Clinical Trials as Topic / Q000191:economics* / Q000379:methods*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D016527:Drug Costs; D015276:Health Care Rationing / Q000191:economics; D006801:Humans; D012107:Research Design; D012109:Research Support as Topic; D017211:Treatment Failure; D014481:United States
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab